Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone
- Conditions
- Heart FailureHeart Failure With Reduced Ejection FractionHeart Failure NYHA Class IIHeart Failure NYHA Class IIIHeart Failure NYHA Class IV
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Ahmad Abdullah Salawi
- Target Recruit Count
- 509
- Registration Number
- NCT06641284
- Locations
- 🇸🇦
King Fahd Central Hospital, Al 'Usaylah, Saudi Arabia
Bioequivalence Study of Spironolactone Tablets in Healthy Subjects
- Conditions
- Bioequivalence Study
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- SPH Sine Pharmaceutical Laboratories Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT06579053
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Finerenone for Patients With Primary Aldosteronism (FAIRY)
- Conditions
- Primary Aldosteronism
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Qifu Li
- Target Recruit Count
- 306
- Registration Number
- NCT06457074
- Locations
- 🇨🇳
the first affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China
Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment
- Conditions
- HypertensionGenetic PredispositionDrug Effect
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 38
- Registration Number
- NCT06413082
- Locations
- 🇮🇹
San Raffaele Hospital, Milan, Lombardia, Italy
🇮🇹IRCCS Ospedale San Raffaele, Milan, Italy
Optimal Medical Treatment of Difficult-to-treat Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- National Institute of Cardiology, Warsaw, Poland
- Target Recruit Count
- 2500
- Registration Number
- NCT06275763
- Locations
- 🇵🇱
National Institute of Cardiology, Warsaw, Mazowieckie, Poland
SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 580
- Registration Number
- NCT06204640
Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
- Conditions
- Primary Aldosteronism
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 150
- Registration Number
- NCT06164379
- Locations
- 🇨🇳
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
- Conditions
- Congenital Mitral Insufficiency
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 164
- Registration Number
- NCT06039592
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Study of Drug Therapy for Pediatric Heart Failure
- Conditions
- Heart Failure Congenital
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 200
- Registration Number
- NCT06039540
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
- Conditions
- Congenital Mitral Insufficiency
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 122
- Registration Number
- NCT06037434
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.